Editas Medicine Stock Price and Value Analysis

Should you buy Editas Medicine stock? (NasdaqGS:EDIT). Let's see how it does in our automated value investing analysis system.

EDIT Free Cash Flow Trend

Free Cash Flow trendline for EDIT
Free Cash Flow trendline for Editas Medicine

Hmm, we can't give any reliable projection for Editas Medicine's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has stable growth.
  • This company is not making money.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the EDIT Numbers

EDIT Price
(Editas Medicine stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 13%

Is Editas Medicine Stock on Sale?

Based on our analysis, we believe that you should not buy Editas Medicine right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy EDIT Stock?

Does Editas Medicine have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.